Omeros Corporation announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is the first and only FDA-approved therapy for this often-fatal complication and is indicated for use in both adults and children aged two years and older. The approval follows strong efficacy and safety data, with a U.S. product launch planned for January 2026. No grant or funding from multiple organizations was mentioned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251224065139) on December 24, 2025, and is solely responsible for the information contained therein.